Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roberto Ravasio

Showing results (11-20 of 39) with videos related to

Pageof 4
Sort By:
Global & Regional Health Technology Assessment|December 5, 2024
Roberto Ravasio, Andrea Marcellusi, Luca de Nicola
Global & Regional Health Technology Assessment|January 11, 2023
Paolo Gisondi, Francesco Loconsole, Paola Raimondo, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Roberto Caporali, Roberto Ravasio, Paola Raimondo, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Arianna Bertolani, Roberto Ravasio, Paola Raimondo, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in ItalyRoberto Caporali, Roberto Ravasio, Paola Raimondo, et al.
Clinical Drug Investigation|June 2, 2011
Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysisRoberto Ravasio, Cinzia Ortega, Roberto Sabbatini, et al.
Clinical and Experimental Rheumatology|July 8, 2016
Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritisIgnazio Olivieri, Caterina Fanizza, Michele Gilio, et al.
Italian Journal of Pediatrics|June 3, 2014
Analysis of the cost-effectiveness of surfactant treatment (Curosurf®) in respiratory distress syndrome therapy in preterm infants: early treatment compared to late treatmentCarlo Dani, Roberto Ravasio, Leonardo Fioravanti, et al.
Advances in Therapy|July 5, 2016
Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with MethotrexateAlberto Batticciotto, Roberto Ravasio, Marta Riva, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in ItalyRoberto Ravasio, Antonio Costanzo, Silvia Antonelli, et al.
Pageof 4

Showing results (11-20 of 39) with videos related to

Sort By:
Pageof 4
Global & Regional Health Technology Assessment|December 5, 2024
Roberto Ravasio, Andrea Marcellusi, Luca de Nicola
Global & Regional Health Technology Assessment|January 11, 2023
Paolo Gisondi, Francesco Loconsole, Paola Raimondo, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Roberto Caporali, Roberto Ravasio, Paola Raimondo, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Arianna Bertolani, Roberto Ravasio, Paola Raimondo, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in ItalyRoberto Caporali, Roberto Ravasio, Paola Raimondo, et al.
Clinical Drug Investigation|June 2, 2011
Bevacizumab plus interferon-α versus sunitinib for first-line treatment of renal cell carcinoma in Italy: a cost-minimization analysisRoberto Ravasio, Cinzia Ortega, Roberto Sabbatini, et al.
Clinical and Experimental Rheumatology|July 8, 2016
Efficacy, safety and cost per responder of biologics in the treatment of non-radiographic axial spondyloarthritisIgnazio Olivieri, Caterina Fanizza, Michele Gilio, et al.
Italian Journal of Pediatrics|June 3, 2014
Analysis of the cost-effectiveness of surfactant treatment (Curosurf®) in respiratory distress syndrome therapy in preterm infants: early treatment compared to late treatmentCarlo Dani, Roberto Ravasio, Leonardo Fioravanti, et al.
Advances in Therapy|July 5, 2016
Efficacy and Treatment Costs of Monotherapy with bDMARDs in the Treatment of Rheumatoid Arthritis in Patients Intolerant to or Inappropriate to Continue Treatment with MethotrexateAlberto Batticciotto, Roberto Ravasio, Marta Riva, et al.
Global & Regional Health Technology Assessment|January 11, 2023
Number needed to treat for interleukin inhibitors approved for the treatment of moderate-to-severe plaque psoriasis in ItalyRoberto Ravasio, Antonio Costanzo, Silvia Antonelli, et al.
Pageof 4